Castuner

Applied Clinical Trials

Applied Clinical Trials

Go behind the pages of Applied Clinical Trials

Web del podcast

Escolta'l a la teva aplicació

Episodis

331 episodis

  1. ACT Brief: APAC Sponsor Priorities, Continuous Glucose Monitoring Trials, and GLP-1 Eye Warning 1:52
  2. ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval 1:41
  3. ACT Brief: China’s Startup Timelines, AI-Drafted Clinical Study Reports, and Bimzelx Psoriatic Arthritis Data 1:47
  4. ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval 1:47
  5. ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment 1:39
  6. ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal 1:54
  7. The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time 43:12
  8. ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal 1:57
  9. ACT Brief: Embedding AI Across Operations, Faster Trial Decisions, and Voceryq Approval 1:36
  10. ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval 1:49
  11. ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance 1:51
  12. ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases 1:48
  13. ACT Brief: Legacy Trial Workflows, Medical Writing Talent Gaps, and Post-Exposure COVID Prevention 1:35
  14. ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval 1:52
  15. ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act 1:54
  16. ACT Brief: Applied Clinical Trials at 2026 SCRS Global Site Solutions Summit 1:57
  17. ACT Brief: AI Operating Models, Oncology Evidence Trust, and Thyroid Eye Disease Approval 1:25
  18. ACT Brief: Who Sets Trial Endpoints, Human-Centered Trial Execution, and Bladder Cancer Approval Expansion 1:50
  19. The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution 39:28
  20. ACT Brief: EHR-to-EDC Connectivity, FDA’s Rare Disease Framework, and Barriers to Oncology RWE 1:55
  21. ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License 1:59
  22. AI and Patient Recruitment: Can Predictive Promise Drive True Transformation? 27:06
  23. ACT Brief: RBQM Analysis Frequency, Building Trust in Oncology Data, and Rare Pediatric PRV Monetization 1:50
  24. ACT Brief: AI and Protocol Design, Site Training Readiness, and GLP-1 Unmet Needs 1:47
  25. ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction 1:56
  26. ACT Brief: Ibogaine Trial Design Guidance, Outsourcing Model Oversight Gaps, and Kidney Disease Partnership 1:51
  27. ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination 1:42
  28. ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment 1:52
  29. ACT Brief: AI as Design Advisor, Autonomous Agent Governance, Oral Weight-Loss Therapy Switch 1:54
  30. ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill 1:40
  31. ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals 1:51
  32. ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval 1:52
  33. ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy 1:55
  34. ACT Brief: Data Provenance and Device Strategy, Cell-Gene Therapy Site Readiness, and Data Harmonization Bottleneck 2:07
  35. Beyond Compliance: Vivalink's Cecilia Xi, PhD, on Data Provenance and Sustainable Device Strategy in Clinical Trials 21:27
  36. ACT Brief: Patient Journey and Study Design, Decentralization's True Cost, and Europe's Pharma Competitiveness Crisis 1:51
  37. ACT Brief: Patient-Site Interaction and Technology, AI Pilot Success Requires Discipline, and CagriSema Beats Lilly Drug 1:38
  38. ACT Brief: Patient-Site Trust and AI Role, Platform Approach to Scale, Gene Therapy for Pediatric Disease 1:39
  39. ACT Brief: Patient Voice as Methodology, AI System Bottlenecks, Regulatory Convergence on Patient Input 1:47
  40. ACT Brief: Expedited IND Pilot Launch, Operating Model Importance, and Readiness Prediction 1:45
  41. The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data 43:33
  42. ACT Brief: Epilepsy Trial Feasibility and Family Realities, CRO Partnerships and Strategic Value, and Cortisol and GLP-1 Response 1:52
  43. ACT Brief: Endpoint Selection and Patient Engagement, Execution Infrastructure Before AI, and Real-World Data Quality Gaps 1:37
  44. ACT Brief: Epilepsy Trial Endpoints, Lab Orchestration and Scientific Intent, and Systems Over Point Solutions 1:51
  45. ACT Brief: Patient Voice in Protocol Design, AI-Informed Recruitment Workflows, and Engagement Maturity Beyond Performative 1:25
  46. ACT Brief: Explainable AI for Patient Subgroups, Participant Understanding and Engagement, and FDA Leadership Stabilization 1:51
  47. Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable 23:40
  48. ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis 1:46
  49. ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD 1:39
  50. ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files 1:41